Tuesday, June 30, 2015

Top 10 Net Payout Yield Companies To Own For 2016

Top 10 Net Payout Yield Companies To Own For 2016: NutriSystem Inc(NTRI)

Nutrisystem, Inc. provides weight management products and services in the United States. The company offers nutritionally balanced weight loss programs designed for women, men, and seniors. Its Nutrisystem program consists of approximately 130 portion-controlled items that serve as the foundation of a low Glycemic Index diet. The company?s programs include Nutrisystem D program designed for people with type 2 diabetes for loosing weight and managing their diabetes; SUCCESS program designed to take the weight off and keep it off through portion-controlled, balanced nutrition, and low Glycemic Index eating; and Nutrisystem Select, a program for weight loss and weight management that offers standard shelf-stable food and fresh-frozen foods. It also provides monthly food packages of shelf-stable and frozen foods consisting of 28 days of breakfasts, lunches, dinners, and desserts, which are supplemented with dairy, fruits, salads, vegetables, and low-glycemic carbohydrate item s. In addition, the company offers transition and maintenance plans that comprise support tools and desired meal occasions, as well as online and smart phone weight management tools. Nutrisystem, Inc. sells its pre-packaged foods to weight loss program participants directly through the Internet and telephone, as well as through QVC, a television shopping network. The company was founded in 1972 and is based in Fort Washington, Pennsylvania.

Advisors' Opinion:
  • [By Ben Levisohn]

    Shares of Weight Watchers have gained 23% to $24.36 at 11:27 a.m., while NutriSystem (NTRI) has gained 2.4% to $15.36 and Medifast (MED) has dropped 1.6% to $31.15.

  • source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/top-10-net-payout-yield-companies-to-own-for-2016.html

Sunday, June 28, 2015

Hot Electric Utility Companies To Invest In Right Now

Hot Electric Utility Companies To Invest In Right Now: InterDigital Inc.(IDCC)

Interdigital, Inc. engages in the design and development of digital wireless technology solutions. The company offers technology solutions for use in digital cellular and wireless products and networks, including 2G, 3G, 4G, and IEEE 802-related products and networks. It holds patents related to the fundamental technologies that enable wireless communications. The company licenses its patents to equipment producers that manufacture, use, and sell digital cellular and IEEE 802-related products; and licenses or sells mobile broadband modem solutions, including modem IP, know-how, and reference platforms to mobile device manufacturers, semiconductor companies, and other equipment producers that manufacture, use, and sell digital cellular products. InterDigital?s solutions are incorporated in various products comprising mobile devices, such as cellular phones, tablets, notebook computers, and wireless personal digital assistants; wireless infrastructure equipment, such as base stations; and components, dongles, and modules for wireless devices. The company was founded in 1972 and is headquartered in King of Prussia, Pennsylvania.

Advisors' Opinion:
  • [By Jayson Derrick]

    InterDigital (NASDAQ: IDCC) won a Delaware infringement suit against ZTE.

    Related: InterDigital Traders Selling On News After Buying On Rumors

  • [By MONEYMORNING.COM]

    In addition to Microsoft, tech companies that China has targeted include San Diego-based Qualcomm Inc. (Nasdaq: QCOM), and Delaware-based InterDigital Inc. (Nasdaq: IDCC).

  • [By Dan Caplinger]

    Friday gave stock market investors some respite from losses earlier in the week, as major-market benchmarks managed to recover by around a quarter of a percent. Merger and acquisition activity helped bolst! er stocks in many different parts of the market, but concerns about the sustainability of the economic recovery held others back. Finisar (NASDAQ: FNSR  ) , InterDigital (NASDAQ: IDCC  ) , and GNC Holdings (NYSE: GNC  ) were among the worst performers of the day.

  • [By Maria Armental var popups = dojo.query(".socialByline .popC"); popups.forEach]

    Among the companies with shares expected to actively trade in Tuesday’s session are Hillshire Brands Co.(HSH), InterDigital Inc.(IDCC) and Krispy Kreme Doughnuts Inc.(KKD)

  • source from Top Stocks For 2015:http://www.topstocksblog.com/hot-electric-utility-companies-to-invest-in-right-now.html

Tuesday, June 23, 2015

10 Best Freight Stocks To Watch For 2016

10 Best Freight Stocks To Watch For 2016: Chalmers Ltd (CHR)

Chalmers Limited is an Australia-based company engaged in transport, logistic services, warehousing and container storage, repairs and sales. The Company operated in three segments: Transport, Containers and Property. Transport consists of road transport, predominantly import/export FCL containers and the interface with logistics/ warehousing/hubbing services. Containers represent the empty container park operations concerned with handling, storage, repairs, upgrades, pretrips and so on of empty containers on behalf of shipping and leasing company customers. Property represents the capital investment Chalmers has in freeholds located in Melbourne. The Company's subsidiaries include Chalmers Industries Pty Ltd, Chalmers (Australia) Pty Ltd and Chalmers Industries (Brisbane) Pty Ltd. Advisors' Opinion:
  • [By Corinne Gretler]

    Chr. Hansen A/S (CHR) slid 1.7 percent to 186 kroner after Credit Suisse Group AG cut the stock to neutral, the equivalent of hold, from outperform. The brokerage said that profit from its natural-color business remains under pressure. The world's biggest maker of dairy enzymes cut its full-year sales forecast on July 3 because of lower prices for the red pigment carmine.

  • source from Top Stocks For 2015:http://www.topstocksblog.com/10-best-freight-stocks-to-watch-for-2016.html

Sunday, June 21, 2015

Best Cheapest Stocks For 2015

The banks are suffering again and this gives me a very good opportunity to increase my understanding of their business. After looking at the balance sheet and the leverage of a bank, today we are moving to more interesting things. In this article, I will look at ways to come up with an idea of how a particular bank does its business. Understanding the business model, the lending practices, the growth the bank expects is very important before jumping in. This will be a differentiator between a good and less speculative investment to a haphazard and highly speculative one.

If within reasons we can come up with a way to measure the management and the business model of a bank, then we will have a better confidence in putting our money in the bank. Let us look at these issues in more detail.

Measuring growth

Deposit growth is one of the first things to look at. The historical figure will tell you if the bank has been able to attract money from its customers. As we have seen and discussed before, customer deposits are the cheapest way for a bank to get money. If a bank is not getting enough raw material from customers, it will have to borrow funds from less attractive venues, like debt offering, equity offering, or borrowing from other banks.

5 Best Gas Utility Stocks For 2016: Altera Corporation (ALTR)

Altera Corporation, a semiconductor company, designs, manufactures, and markets programmable logic devices (PLD), HardCopy application-specific integrated circuit (ASIC) devices, pre-defined design building blocks, and associated development tools. Its PLDs consist of field-programmable gate arrays (FPGAs) and complex programmable logic devices (CPLDs), which are semiconductor integrated circuits manufactured as standard chips that can be programmed to perform logic functions in electronic systems; and HardCopy structured ASIC devices that transition customer designs from high-density FPGAs to low-cost non-programmable implementations for volume production. The company?s products primarily include Stratix series high-end, system-level FPGAs; Arria series mid-range, transceiver-equipped FPGAs; Cyclone series low-cost FPGAs; MAX series CPLDs; and HardCopy ASICs. It also offers intellectual property cores that are pre-verified building blocks that execute system-level functio ns that is incorporated into the PLD design; and development tools consisting primarily of the Quartus II software for design entry, design compilation, design verification, and device programming. Altera Corporation serves customers primarily in the telecom and wireless, industrial automation, military and automotive, networking, and computer and storage markets. The company markets its products through a network of distributors, independent sales representatives, and direct sales personnel. It has operations in the Americas, the Asia Pacific, Europe, the Middle East, Africa, and Japan. The company was founded in 1983 and is headquartered in San Jose, California.

Advisors' Opinion:
  • [By kcpl]

    Altera�(ALTR)'s performance has been weak as shares are down almost 9% so far this year as compared to peers such as Xilinx (XLNX) and Lattice Semiconductor.

  • [By gurujx]

    Altera Corp. (ALTR) Reached the 3-year Low of $30.86

    The prices of Altera Corp. (ALTR) shares have declined to close to the 3-year low of $30.86, which is 40.3% off the 3-year high of $49.59.

  • [By Beth Piskora]

    They are listed below:

    Altera (ALTR)��ielding 1.7%

    Apple (AAPL)��ielding 2.5%

    Applied Materials (AMAT)��ielding 2.6%

    Cisco (CSCO)��ielding 2.9%

    EMC Corp. (EMC)��ielding 1.5%

    International Business Machines (IBM)��ielding 2.0%

    KLA-Tencor (KLAC)��ielding 3.2%

    Microchip Technology (MCHP)��ielding 3.6%

    Oracle (ORCL)��ielding 1.5%

    Qualcomm (QCOM)��ielding 2.1%

    Texas Instruments (TXN)��ielding 2.9%

    Xilinx (XLNX)��ielding 2.3%

    Subscribe to S&P's The Outlook here��/P>

Best Cheapest Stocks For 2015: Dollar/Yen (YY)

YY Inc., through its subsidiaries, operates an online social platform in the People�s Republic of China. It provides YY Client, a personal computer based user software that offers real-time access to user-created online social activities groups. The company also offers Web-based YY that enables users to conduct real-time interactions on the Web without any downloads or installations; and Mobile YY, a smartphone application. In addition, it operates Duowan.com, a game media Website that provides information on online games and other resources for users and online game players. The company was founded in 2005 and is based in Guangzhou, the People�s Republic of China.

Advisors' Opinion:
  • [By Michael Cintolo]

    This has created huge opportunities for companies like YY Inc. (YY), the wildly popular Chinese online social platform that's still evolving.

    The core of YY's appeal is software that allows users to interact online in real time without any downloads or installations.

Best Cheapest Stocks For 2015: Derma Sciences Inc.(DSCI)

Derma Sciences, Inc. operates as a medical technology company. The company provides advanced wound care products, including Medihoney dressings that are used for the management of non-chronic and hard-to-heal wounds, such as chronic ulcers, burns, and post-operative wounds; Bioguard dressings that are used for prophylactic use in the prevention of hospital or community acquired infections through wound sites; Algicell Ag, antimicrobial dressings; Xtrasorb dressings that convert fluid within the dressings to a gel and lock the exudates into the dressings; TCC-EZ, a dressing system for the management of diabetic foot ulcers; and occlusive dressings, such as hydrocolloids, foams, hydrogels, alginates, additional silver antimicrobial dressings, cleansers, and Dermagran products. It also offers traditional wound care products, such as of gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages, and other compression devices, as well as a dhesive bandages and related first aid products. In addition, the company provides pharmaceutical wound care products, including DSC127, an angiotensin analog for use in wound healing and scar reduction. It markets wound closure strips, nasal tube and catheter fasteners, barrier creams and ointments, antibacterial cleansing foams and sprays, shampoos and body washes, hand sanitizers, bath additives, body oils, and moisturizers to doctors, clinics, nursing homes, hospitals, home healthcare agencies, and other institutions. The company sells its products to health care providers, such as wound care centers, extended care facilities, acute care facilities, home health care agencies, and physicians? offices through direct sales representatives in the United States, Canada, and the United Kingdom; retail channels; manufacturers? representatives and independent distributors in international markets. Derma Sciences, Inc. was founded in 1984 and is headquartered in Princeton, New Jersey.

Advisors' Opinion:
  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Derma Sciences (Nasdaq: DSCI  ) , whose recent revenue and earnings are plotted below.

  • [By Alexander Maxwell]

    Grafix has raised the bar on chronic diabetic foot ulcer treatment. Another company developing treatments for CDFU is Derma Sciences� (NASDAQ: DSCI  ) . Derma is developing a treatment called DSC 127, which is currently in phase 3 trials with results expected in 2015.

  • [By John Udovich]

    Small cap stocks Derma Sciences Inc (NASDAQ: DSCI), Oculus Innovative Sciences, Inc (NASDAQ: OCLS)�and Arch Therapeutics Inc (OTCBB: ARTH) specialize or have a focus on wound care���a medical problem that has plagued mankind since the dawn of time. After all and think back to our Civil War when disease along with infections resulting from improper wound care probably killed more soldiers than actual battles. Even today, infection after surgery or after receiving a wound or injury of any kind is still a constant threat. And then there is the scaring that can result from any sort of invasive surgery or injury. With those thoughts in mind, here are three small cap wound care stocks trying address these problems:

Best Cheapest Stocks For 2015: Macquarie Infrastructure Company LLC (MIC)

Macquarie Infrastructure Company LLC (MIC) owns, operates and invests in a diversified group of infrastructure businesses that provide basic services, such as chilled water for building cooling and gas utility services to businesses and individuals primarily in the United States. The businesses it owns and operates include individual segments with three of them grouped as the Energy-Related Businesses. Macquarie Infrastructure Management (USA) Inc. (MIMUSA), which is its Manager, is part of the Macquarie Group, consisting of Macquarie Group Limited and its subsidiaries and affiliates worldwide. On August 31, 2011, Atlantic Aviation acquired the assets of the FBOs at the Portland International and Eugene airports in Oregon (together referred to as Flightcraft).

The Energy-Related Businesses include a 50% interest in a bulk liquid storage terminal business (International Matex Tank Terminals (IMTT)), that provides bulk liquid storage and handling services at ten marine terminals in the United States and two in Canada and is a participant in this industry in the United States, based on storage capacity; a gas processing and distribution business (The Gas Company), that is the only full-service gas energy company in Hawaii, and a 50.01% controlling interest in a district energy business (District Energy), which operates a district cooling system in the United States, serving various customers in Chicago, Illinois and Las Vegas, Nevada. Atlantic Aviation is an airport services business providing products and services, including fuel and aircraft hangaring/parking, to owners and operators of general aviation aircraft at 65 airports in the United States.

Energy-Related Businesses

MIC owns 50% of IMTT. The remaining 50% is owned by a trust for the benefit of members of the founding family. IMTT stores and handles petroleum products, various chemicals, renewable fuels and vegetable and animal oils. IMTT is an independent provider of bulk liquid storage terminal services i! n the United States, based on capacity. IMTT also owns OMI Environmental Solutions (Oil Mop), which is an environmental emergency responses, industrial services, waste transportation and disposal business. Oil Mop has a network of facilities along the United States Gulf Coast between Houston and New Orleans. These facilities primarily service the Gulf region, but also respond to spill events and provides services as needed throughout the United States and internationally. The 16 million barrel storage terminal at Bayonne, New Jersey has the most storage capacity of any IMTT site.

NYH serves as the main petroleum trading hub in the northeast United States and the physical delivery point for the gasoline and heating oil futures contracts traded on New York Mercantile Exchange (NYMEX). In addition to waterborne shipments, products reach NYH through petroleum product pipelines from the United States Gulf region and elsewhere. NYH also serves as the starting point for refined product pipelines linked to inland markets and as a key port for refined petroleum product exports. IMTT-Bayonne has connections to the Colonial, Buckeye and Harbor refined petroleum product pipelines, as well as rail and road connections. As of December 31, 2011, on the lower Mississippi River, IMTT operated four terminals (St. Rose, Gretna, Avondale and Geismar). With combined storage capacity of 18.9 million barrels, the four sites give IMTT substantial market share in storage for black oil, bulk liquid chemicals, and vegetable oils on the lower Mississippi River.

The Gas Company is Hawaii�� only government franchised full-service gas company, manufacturing and distributing gas products and services in Hawaii. The market includes Hawaii�� approximately 1.4 million residents and approximately 7.3 million visitors, during the year ended December 31, 2011. The Gas Company manufactures synthetic natural gas (SNG) for its utility customers on Oahu, and distributes Liquefied Petroleum Gas (LPG) to utility and ! non-utili! ty customers throughout the state�� six primary islands. The Gas Company has two primary businesses, utility (or regulated) and non-utility (or unregulated). The utility business serves approximately 35,300 customers through localized pipeline distribution systems located on the islands of Oahu, Hawaii, Maui, Kauai, Molokai and Lanai. Over 90% of these customers are on Oahu. The utility business includes the manufacture, distribution and sale of SNG on the island of Oahu and distribution and sale of LPG. Utility revenue consists principally of sales of SNG and LPG.

The non-utility business sells and distributes LPG to approximately 33,400 customers. LPG is delivered by truck to individual tanks located on customer sites on Oahu, Hawaii, Maui, Kauai, Molokai and Lanai. Non-utility revenue is generated primarily from the sale of LPG delivered to customers. SNG and LPG have a number of commercial and residential applications, including water heating, drying, cooking, emergency power generation and decorative lighting, such as tiki torches. LPG is also used as a fuel for specialty vehicles, such as forklifts. Gas customers include residential customers and a range of commercial, hospitality, military, public sector and wholesale customers. SNG is delivered by underground piping systems to customers on Oahu. LPG is transported in cylinders or tanks.

District Energy operates district cooling system in the United States. As of December 31, 2011, the system served approximately 100 customers in downtown Chicago and one customer outside the downtown area under long-term contracts. District Energy produces chilled water at five plants located in downtown Chicago and distributes it through a closed loop of underground piping for use in the air conditioning systems of large commercial, retail and residential buildings in the central business district. District Energy also owns a site-specific heating and cooling plant that serves a single customer in Chicago outside the downtown area. Th! is plant ! has the capacity to produce 4,900 tons of cooling and 58 million British Thermal Units of heating per hour. District Energy�� Las Vegas operation owns and operates a stand-alone facility that provides cold and hot water (for chilling and heating, respectively) to three customers in Las Vegas, Nevada. These customers consist of a resort and casino, a condominium.

Aviation-Related Business

Atlantic Aviation operates FBOs at 65 airports in the United States. Atlantic Aviation�� FBOs provide fueling and fuel-related services, aircraft parking and hangar services to owners/operators of jet aircraft, primarily in the general aviation sector of the air transportation industry, but also commercial, military, freight and government aviation customers. Other services include de-icing, aircraft parking, hangar rental and catering. Fuel is stored in fuel tank farms and each FBO operates refueling vehicles owned or leased by the FBO. The FBO either owns or has access to the fuel storage tanks to support its fueling activities. At some of Atlantic Aviation�� locations, services are also provided to commercial carriers. These may include refueling from the carrier�� own fuel supplies stored in the carrier�� fuel farm, de-icing and/or ground and ramp handling services.

The Company competes with Bahamas Oil Refining Company International Limited; Buckeye Partners, L.P.; Enterprise Products Partners L.P.; Houston Fuel Oil Terminal Company; Kinder Morgan Energy Partners, L.P.; Magellan Midstream Partners, L.P.; NuStar Energy L.P.; Oiltanking Partners, L.P.; Plains All American Pipeline, L.P.; Royal Vopak N.V.; Sunoco Logistics Partners L.P.; TransMontaigne Partners L.P.; Vitol Holding B.V.; Westway Group, Inc.; Alinda Capital Partners LLC; ArcLight Capital Partners; Challenger Infrastructure Fund; First Reserve Corporation, Global Infrastructure Partners, Signature Flight Support, Landmark Aviation and Million Air.

Advisors' Opinion:
  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Macquarie Infrastructure (NYSE: MIC  ) , whose recent revenue and earnings are plotted below.

  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Macquarie Infrastructure (NYSE: MIC  ) , whose recent revenue and earnings are plotted below.

  • [By Garrett Cook]

    Macquarie Infrastructure Company LLC (NYSE: MIC) shares shot up 10.72 percent to $67.73 after the company agreed to acquire the remaining 50% of International-Matex Tank Terminals for $910 million in cash and $115 million in newly issued stock. It also raised its quarterly dividend from $0.9375 to $0.95 per share.

  • [By Eddie Staley]

    Macquarie Infrastructure Company LLC (NYSE: MIC) shares shot up 11.59 percent to $68.26 after the company agreed to acquire the remaining 50% of International-Matex Tank Terminals for $910 million in cash and $115 million in newly issued stock. It also raised its quarterly dividend from $0.9375 to $0.95 per share.

Best Cheapest Stocks For 2015: Steven Madden Ltd.(SHOO)

Steven Madden, Ltd., together with its subsidiaries, designs, sources, markets, and sells fashion-forward name brand and private label footwear for women, men, and children. It offers wholesale footwear under the Steve Madden Women?s, Madden Girl, Steve Madden Men?s, Steven, l.e.i., Elizabeth and James, Olsenboye, Stevies, Big Buddha Shoes, Madden, Betsey Johnson shoes, Report, and Superga to department stores, mid-tier department stores, better specialty stores, and independently owned boutiques in the United States. The company also provides wholesale handbags and accessories under the Daisy Fuentes, Olsenboye, Steve Madden, Steven by Steve Madden, Betsey Johnson, Betseyville, and Big Buddha brand names, as well as sells cold weather accessories, fashion scarves, wraps, and other trend accessories primarily under the Cejon and Steve Madden brand names to department stores and specialty stores. As of December 31, 2011, it operated 84 retail stores, including 73 Steve Ma dden full price stores, 6 Steve Madden outlet stores, 3 Steven stores, 1 Report store, and 1 e-commerce Website. In addition, the company licenses its Steve Madden and Steven by Steve Madden trademarks for use in connection with the manufacturing, marketing, and sale of cold weather accessories, sunglasses, eyewear, outerwear, bedding, hosiery and women?s fashion apparel, jewelry, and luggage, as well as licenses Betsey Johnson and Betseyville trademarks for sale of apparel, jewelry, swimwear, eyewear, watches, fragrances, and outerwear. Steven Madden, Ltd. distributes its products through its retail stores and e-commerce Website in department stores, specialty stores, luxury retailers, national chains, and mass merchants in the United States; and through special distribution arrangements in Asia, Canada, Europe, the Middle East, Mexico, Australia, Central and South America, and India. The company was founded in 1990 and is headquartered in Long Island City, New York.

Advisors' Opinion:
  • [By DAILYFINANCE]

    David Tulis/AP It's beginning to look a lot like ... the day after Christmas? On the day before Christmas, retailers turned shoppers' attention to the day after the holiday. Amazon.com (AMZN) already is offering "after Christmas" deals of up to 70 percent off clothes and 60 percent off some electronics. Old Navy (GPS) is running TV ads that its "after-holiday sale starts early" with discounts of up to 75 percent off. And CVS (CVS) was selling a wine cabinet for $10 off at $39.99 and three fleece throws for $9.99 on Christmas Eve. Heather Nadler, 38, stopped by the CVS in Decatur, Ga., on Tuesday, searching for stuffed animals for her children. But she still plans to hit up sales after Christmas. "I'll probably start shopping for me at that point," she said. Stores usually wait until after Christmas to offer discounts of up to 70 percent or more on holiday merchandise that didn't sell. But Americans who are still worried about the economy have held tightly to their purse strings this year, and store sales have fallen for the past three consecutive weeks. The pre-Christmas deals come as retailers are feeling pressure to attract Americans into stores during the final week of what's typically the busiest shopping period of the year. The two-month stretch that begins on Nov. 1 is important because retailers can make up to 40 percent of their annual sales during that time. Sales at U.S. stores dropped 3.1 percent to $42.7 billion for the week that ended on Sunday compared with the same week last year, according to ShopperTrak, which tracks data at 40,000 locations. That follows a decline of 2.9 percent and 0.8 percent during the first and second weeks of the month, respectively. Stores had a problem even getting Americans into stores, let alone getting them to spend. The number of shoppers fell 21.2 percent during the week that ended on Sunday, according to ShopperTrak. Karen McDonald, a spokeswoman at Taubman Centers, which owns or operates 28 malls, estima

Best Cheapest Stocks For 2015: Dean Foods Company(DF)

Dean Foods Company, together with its subsidiaries, operates as a food and beverage company in the United States. It operates in two segments, Fresh Dairy Direct-Morningstar and WhiteWave-Alpro. The Fresh Dairy Direct-Morningstar segment manufactures, markets, and distributes various branded and private label dairy case products, including cream, ice cream mix, and ice cream novelties; creamers and other extended shelf life fluids; yogurt, cottage cheeses, sour creams, and dairy-based dips; fruit juices, fruit-flavored drinks, iced teas, and water; half-and-half and whipping creams; and items for resale, such as butter, cheese, eggs, and milk shakes. This segment sells its dairy case products to retailers, distributors, foodservice outlets, educational institutions, and governmental entities. The WhiteWave-Alpro segment manufactures, develops, markets, and sells various branded dairy and dairy-related products, such as milk and other dairy products; organic dairy products; plant-based beverages, such as soy, almond, and coconut milks; and soy food products, coffee creamers, and creamers and fluid dairy products. It also provides branded soy-based beverages and food products in Europe under the Alpro and Provamel brands. This segment sells its products to various customers, including grocery stores, club stores, natural foods stores, mass merchandisers, convenience stores, drug stores, and foodservice outlets. The company was formerly known as Suiza Foods Corporation and changed its name to Dean Foods Company on December 21, 2001 as a result of merger between the former Dean Foods Company and Suiza Foods Corporation. Dean Foods Company was founded in 1995 and is headquartered in Dallas, Texas.

Advisors' Opinion:
  • [By John Maxfield]

    Meanwhile, the worst-performing stock on the index was Dean Foods (NYSE: DF  ) , which lost more than half of its value. This otherwise disturbing performance followed the company's spinoff of its organic-foods division, WhiteWave Foods (NYSE: WWAV  ) . As fellow Fool Rich Duprey covered here, each Dean Foods shareholder received 0.25544448 shares of WhiteWave class A stock and 0.36380189 shares of its class B stock for every share of Dean Foods.

  • [By Johanna Bennett]

    Whys is Dean Foods (DF) having such a bad day? Well, blame someof it on�all those milk drinkers in New Zealand.

    Dean reported a wider-than-expected second-quarter loss and warned it will post another loss in the third quarter. For the period ended June 30, Dean posted an operating loss of 14 cents a share, compared with 26 cents a share 12 months ago. The company had expected a loss of 2 cents to 8 cents a share. Net sales climbed 7.5% to $2.39 billion.

    Why the�dire quarter? The largest milk producer in the U.S. is struggling with surging costs for the raw milk it buys from farmers casued by�heavy�overseas demand for U.S. dairy products and last year’s drop in�production in�New Zealand and other�big dairy producing cuntries. Dean added that it faced difficulty passing on the higher costs because it risked lower sales volumes at supermarkets, where sales trends have been weak amid a year-long decline in milk consumption.

    As of the closing bell, Dean Foods had fallen almost 4% to end the day at $15.19

  • [By Jacob Roche]

    It's clear that this isn't just a problem with the grocery stores themselves. Dean Foods (NYSE: DF  ) , essentially the Pinnacle Foods of milk products, had flat sales growth from 2007 to 2011, just like conventional grocers. White Wave Foods, Dean's former organic milk subsidiary and recent spinoff, had impressive 64%�growth during that time.

  • [By Sara Murphy]

    But what does "organic" really mean, and does the label meet consumers' expectations? Do shoppers know that the Horizon Organics brand -- darling of the urban food co-op -- belongs to decidedly conventional Dean Foods (NYSE: DF  ) ? Or that Hain Celestial (NASDAQ: HAIN  ) has been dogged recently by accusations of false organic labeling, leading to a class action lawsuit?

Best Cheapest Stocks For 2015: Memorial Production Partners LP (MEMP)

Memorial Production Partners LP incorporated on April 4, 2011, is a limited partnership formed by Memorial Resource to own, acquire and exploit oil natural gas properties in North America. As of December 31, 2012, the Company�� total estimated proved reserves were approximately 609 Billions of Cubic Feet Equivalent (Bcfe), of which approximately 62% were natural gas and 59% were classified as proved developed reserves. As of December 31, 2012, the Company produced from 1,671 gross (731 net) producing wells across its properties, with an average working interest of 44%. On April 1, 2012, it acquired oil and natural gas producing properties in East Texas from Memorial Resource Development LLC. In May 2012, it acquired oil and natural gas properties in East Texas and North Louisiana. Effective April 1, 2012, the Company acquired certain oil and natural gas properties in East Texas from Memorial Resource Development LLC. In October 2012, the Company acquired oil and natural gas properties in East Texas from Goodrich Petroleum Corporation. On December 12, 2012, the Company acquired oil and gas producing properties offshore Southern California from Rise Energy Partners, LP. In March 2013, the Company announced that it has closed its acquisition of certain oil and natural gas producing properties in East Texas and North Louisiana from its sponsor, Memorial Resource Development LLC. In September 2013, Memorial Production Partners LP closed two separate transactions to acquire certain oil and natural gas properties from third parties in East Texas and in the Rockies. In October 2013, the Company acquired oil and natural gas properties in the Permian Basin, East Texas, and the Rockies.

The Company�� properties are located in South and East Texas and consist of mature, legacy onshore oil and natural gas reservoirs. The Partnership Properties consist of operated working interests in producing and undeveloped leasehold acreage and in identified producing wells in South and East Texas, and non-ope! rated working interests in producing and undeveloped leasehold acreage. As of December 31, 2012, approximately 58% of its estimated proved reserves and approximately 53% of its average daily net production were located in the East Texas/North Louisiana region. Its East Texas/Louisiana properties include wells and properties located in Navarro, Anderson, Wood, Upshur, Gregg, Harrison, Rusk, Panola, Leon, Polk, Smith, Tyler and Shelby Counties, Texas and De Soto and Lincoln Parishes, Louisiana. Its East Texas/North Louisiana properties include properties in the Joaquin and Carthage fields in Panola and Shelby Counties, the Willow Springs field located in Gregg County, the East Henderson field located in Rusk County, and the Terryville field located in Lincoln Parish.

As of December 31, 2012, approximately 27% of its estimated proved reserves and approximately 35% of average daily net production were located in the South Texas region. Its South Texas properties include wells and properties in numerous natural gas weighted fields located in McMullen, Live Oak, Duval, Jim Hogg, Webb and Zapata Counties, Texas, including the NE Thompsonville, Laredo and East Seven Sisters fields. The Company�� South Texas properties contained 167 Bcfe of estimated net proved reserves as of December 31, 2012. The Company�� Beta properties, consist of a 51.75% working interest and a 35.03% average net revenue interest in three Pacific Outer Continental Shelf blocks (P-0300, P-0301 and P-0306); a 4.575% overriding royalty interest in the Beta unit; a 51.75% undivided interest in two wellbore production platforms with permanent drilling equipment systems and one production handling and processing platform, and a 51.75% controlling equity interest in a 17.5-mile pipeline and an onshore tankage and metering facility. The Company�� Beta properties include a 51.75% undivided interest in Ellen and Eureka platforms. The Beta properties include a controlling interest in the San Pedro Bay Pipeline Company, which owns a! nd operat! es a 16-inch diameter oil pipeline.

Advisors' Opinion:
  • [By Robert Rapier]

    I am going to address LRR Energy LP (NYSE: LRE) and Memorial Production Partners LP (NASDAQ: MEMP) in an upcoming issue of MLP Investing Insider.

    (Follow Robert Rapier on Twitter, LinkedIn, or Facebook.)

  • [By CRWE]

    Memorial Production Partners LP (Nasdaq:MEMP) reported that it has signed a definitive agreement to acquire certain oil and natural gas properties in East Texas from Goodrich Petroleum Corporation, for a purchase price of $95 million, subject to customary purchase price adjustments.

  • [By Aimee Duffy]

    Distributions are incredibly important to master limited partnerships -- they are the reason many investors buy in, and ultimately what drive the market performance for this asset class. As news of distribution increases trickle in for the third quarter, Fool.com contributor Aimee Duffy takes a look at the payouts from Genesis Energy (NYSE: GEL  ) , Plains All American Pipeline (NYSE: PAA  ) , and Memorial Production Partners (NASDAQ: MEMP  ) , as all three MLPs are leading the way with the biggest distribution increases.

Thursday, June 18, 2015

Top 10 Medical Companies To Own For 2015

Popular Posts: 3 Year-to-Date Doublers to Double Down On3 Stocks Going All Out on Stock Buybacks3 Stocks That Are Filling Up the Piggy Bank Recent Posts: Medical Device Companies Still Have Upside, New Tax or Not 7 Top M&A Highlights of Q3 3 Stocks That Are Filling Up the Piggy Bank View All Posts
How to Invest in Obamacare-Era Healthcare

The Affordable Care Act is a once-in-a-lifetime policy change, but it might be too late to make it a once-in-a-lifetime investing opportunity.

Top 10 Prefered Stocks To Buy Right Now: Navidea Biopharmaceuticals Inc (NAVB)

Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, incorporated in 1983, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company�� radiopharmaceutical development programs included Lymphoseek (Lymphoseek, Kit for the Preparation of Technetium Tc99m for Injection), a radiopharmaceutical agent for lymph node mapping; AZD4694, an imaging agent, and RIGScan, a tumor antigen-specific targeting agent. In January 2012, the Company executed an option agreement with Alseres Pharmaceuticals, Inc. (Alseres) to license [123I]-E-IACFT Injection, also called Altropane, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson�� disease, movement disorders and dementia. In August 2011, the Company sold its gamma detection device line of business (the GDS Business) to Devicor Medical Products, Inc.

Lymphoseek

Navidea�� pipeline includes clinical-stage radiopharmaceutical agents used to identify the presence and status of disease. Lymphoseek (Kit for the Preparation of Technetium Tc99m for Injection) is a lymph node targeting agent intended for use in intraoperative lymphatic mapping (ILM) procedures and lymphoscintigraphy employed in the overall diagnostic assessment of certain solid tumor cancers. The lymph system is a component of the body�� immune system. The key components of the lymph system are lymph nodes-small anatomic structures that contain disease-fighting lymphocytes, filter lymph of bacteria and cancer cells, and signal infection in response to heightened levels of pathogens. In Navidea�� Phase III clinical studies of Lymphoseek, it detected over 99% of positive nodes identified by vital blue dye (VBD). As of December 31, 2011, Navidea, in co-operation with UC, San Diego affiliate (UCSD), completed or initiated five Phase I clinical trials, one multi-center Phase II trial and three multi-center Phase II trials inv! olving Lymphoseek. Two Phase III studies were completed in subjects with breast cancer and melanoma. During the year ended December 31, 2011, data from NEO3-09 were released, which indicated that all primary and secondary endpoints for the study were met. As of December 31, 2011, third Phase III clinical trial for Lymphoseek in subjects with head and neck squamous cell carcinoma (NEO3-06) was in progress.

AZD4694

AZD4694 is a Fluorine-18 labeled precision radiopharmaceutical candidate for use in the imaging and evaluation of patients with signs or symptoms of cognitive impairment such as Alzheimer's disease (AD). It binds to beta-amyloid deposits in the brain that can then be imaged in positron emission tomography (PET) scans. Amyloid plaque pathology is a required feature of AD and the presence of amyloid pathology is a supportive feature for diagnosis of probable AD. Patients who are negative for amyloid pathology do not have AD. AZD4694 has been studied in several clinical trials. Clinical studies through Phase IIa have included more than 80 patients to date, both suspected AD patients and healthy volunteers. No significant adverse events have been observed. Results suggest that AZD4694 has the ability to image patients quickly and safely with high sensitivity.

RadioImmunoGuided Surgery

As of December 31, 2011, RIGScan had been studied in a number of clinical trials, including Phase III studies. Navidea has conducted two Phase III studies, NEO2-13 and NEO2-14, of RIGScan in patients with primary and metastatic colorectal cancer, respectively. Both studies were multi-institutional involving cancer treatment institutions in the United States, Israel, and the European Union.

The Company competes with Pharmalucence, Eli Lilly, Bayer Schering, General Electric and GE Healthcare.

Advisors' Opinion:
  • [By Lauren Pollock]

    Navidea Biopharmaceuticals Inc.(NAVB) said the U.S. Food and Drug Administration has granted a priority review for an expanded use of its Lymphoseek drug for some patients with head and neck cancer. Shares dropped 5.4% to $1.97 premarket.

  • [By Erin McCarthy]

    Navidea Biopharmaceuticals Inc.(NAVB) said Chief Executive Mark Pykett would leave that post around the end of this month as the company restructures its biopharmaceutical product pipeline.

Top 10 Medical Companies To Own For 2015: Discount Dental Materials Inc (DDOO)

Discount Dental Materials, Inc. (DDM), incorporated on December 18, 2007, is a development-stage company. The Company focuses on selling disposable dental supply products at discount prices over the Internet. As of November 30, 2011, the Company had not generated any revenues.

The Company focuses on selling a limited number of products including burs (modern dental drills that can rotate at up to 800,000 revolutions per minute (rpm) and generally use hard metal rotary files). Dental burs come in a variety of shapes designed for specific applications. They are often made of steel with a tungsten carbide coating or of tungsten carbide entirely. The bur may also have a diamond coating), bearings, turbines and sterilization pouches. The Company uses a facility in Burbank, California to store and ship products.

The Company competes with Henry Schein and Patterson Dental.

Advisors' Opinion:
  • [By CRWE]

    Last Friday, DDOO previously surged (+5.00%) up +0.05 at $1.05 with 10,200 shares in play at the close (ref. google finance June 28, 2013 ��Close).

    Bond Laboratories, Inc. previously reported NDS launched two exciting new products at the annual GNC庐 Global Franchise Convention.

    Cerebain Biotech Corp. a subsidiary of Discount Dental Materials, Inc. previously reported the appointment of Dr. Surinder Saini as Chairman of its Scientific Advisory Board. The advisory board provides key clinical insight into the company�� efforts to develop and commercialize a novel approach to the treatment for patients suffering from Alzheimer�� disease. Dr. Saini is the lead scientist behind the development of the world’s first medical device specifically designed for the treatment of Alzheimer�� disease utilizing the Omentum

  • [By CRWE]

    Today, DDOO remains (0.00%) +0.000 at $1.00 thus far (ref. google finance Delayed: 10:12AM EDT�June 25, 2013).

    Bond Laboratories, Inc. previously reported NDS launched two exciting new products at the annual GNC庐 Global Franchise Convention.

    Cerebain Biotech Corp. a subsidiary of Discount Dental Materials, Inc. previously reported the appointment of Dr. Surinder Saini as Chairman of its Scientific Advisory Board. The advisory board provides key clinical insight into the company�� efforts to develop and commercialize a novel approach to the treatment for patients suffering from Alzheimer�� disease. Dr. Saini is the lead scientist behind the development of the world’s first medical device specifically designed for the treatment of Alzheimer�� disease utilizing the Omentum

  • [By CRWE]

    Today, DDOO remains (0.00%) +0.000 at $1.05 thus far (ref. google finance Delayed:� 3:42PM EDT July 1, 2013).

    Cerebain Biotech Corp. a subsidiary of Discount Dental Materials, Inc. , previously reported that medical device product development company, Sonos Models, Inc. (��onos��, is set to complete the first prototypes of its medical device solution during the company�� first fiscal quarter, which begins July 1, 2013.

    Cerebain�� President, Eric Clemons, stated, ��e are excited with the imminent completion of the first set of prototypes of our Medical Device Product for the treatment of Alzheimer�� Disease. Years of hard work and research will culminate with the introduction of these prototypes which will utilize the Omentum for the treatment of patients with this debilitating disease. With these prototypes, we are introducing a leading edge approach to the treatment of Alzheimer�� Disease.��/p>

Top 10 Medical Companies To Own For 2015: DiaMedica Inc (DMA)

DiaMedica Inc. (DiaMedica) is a development-stage company. The Company is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. DiaMedica's compound, DM-199, is a recombinant human protein for the treatment of both Type I and Type II diabetes and their complications. DiaMedica is starting a Phase I/II clinical trial for DM-199. DM-199 is a recombinant human protein, which improves glucose control, protects beta cells through the expansion of a population of antigen-specific immunosuppressive cells (Tregs), and proliferates insulin producing beta cells through the activation of certain growth factors. The Company�� DM-204 is a G-protein-coupled receptor agonist (GPCR) monoclonal antibody to treat Type II diabetes and some of the associated complication's. activating a receptor resulted in insulin sensitivity, insulin secretion and vasodilation. Advisors' Opinion:
  • [By Richard Rhodes]

    Given this economic backdrop, and developing pressure on corporate revenues, margins, and earnings, we feel that risk is being misplaced at current levels.

    The 14-day and 40-day models are now overbought. Now, the 14-day and 40-day are peaking, which would certainly indicate a correction stands as the highest probability.

    The % of stocks above their 10-day moving average (dma) is at the 70%-level; still a major divergence with prices.

    The % of stocks above their 200-dma stands at 77%. The 87% level marked previous highs. The 50-dma/150-dma cross breakdown now confirms a larger correction. Bottoms form between 30%-40%.

    Overall, the risk-reward remains skewed to the downside, regardless of whether prices remain above trendline resistance, as our model group suggests a correction to the 110-day moving average, currently at S&P 1711.

    A clear breakdown at that level would accelerate the decline towards the wide 200-dma and 380-dma range, between 1657-1571.

Top 10 Medical Companies To Own For 2015: Foundation Medicine Inc (FMI)

Foundation Medicine, Inc., incorporated on November 12, 2009, is a commercial-stage company. The Company is focused on fundamentally changing the way patients with cancer are treated. The Company�� platform includes methods and algorithms for analyzing tumor tissue samples across all types of cancer, as well as information aggregation and concise reporting capabilities. Its products provide genomic information about each patient�� individual cancer, enabling physicians to optimize treatments in clinical practice and enabling biopharmaceutical companies to develop targeted oncology therapies more effectively.

FoundationOne, its first clinical product, is, to its knowledge, the only commercially available comprehensive molecular information product designed for use in the routine care of patients with cancer. In addition, the Company is considered a non-contracting provider by commercial third-party payors because it has not entered into specific contracts to provide FoundationOne to their covered patients, and as a result it takes on primary responsibility for obtaining reimbursement on behalf of patients.

Advisors' Opinion:
  • [By RedChip]

    According to Walter Isaacson�� biography, Steve Jobs paid a reported $100,000 to learn the DNA sequence of his cancer. This work, completed at MIT and Harvard, led to the launch of Foundation Medicine (NASDAQ: FMI). Foundation Medicine has grabbed headlines over the past couple of weeks as it entered the capital markets with a high-profile IPO led by Goldman Sachs.

  • [By Lisa Levin]

    Foundation Medicine (NASDAQ: FMI) shares tumbled 7.58% to reach a new 52-week low of $21.23. Foundation Medicine's trailing-twelve-month profit margin is -147.08%.

  • [By James E. Brumley]

    It wouldn't be fair to say there's nothing like it "out there", because there is. A company called Foundation Medicine Inc. (NASDAQ:FMI) has developed a similar/comparable app. The CLRX version of the solution appears superior in most ways, however, if for no other reason than because of the projected revenue growth the company is apt to see.

Top 10 Medical Companies To Own For 2015: Vocera Communications Inc (VCRA)

Vocera Communications, Inc. (Vocera), incorporated on February 16, 2000, is a provider of mobile communication solutions. The Company�� solutions consist of its Voice Communication, Messaging and Care Transition solutions. Its Voice Communication solution, which includes a communication badge and a software platform, enables users to connect with other hospital staff. The Company�� Messaging solution delivers text messages and alerts directly to and from smartphones. Its Care Transition solution is a voice and text-based software application that captures, manages and monitors patient information when responsibility for the patient is transferred or handed-off from one caregiver to another, or when the patient is discharged from the hospital. Users can communicate with others using the Vocera communication badge or through Vocera Connect client applications available for BlackBerry, iPhone and Android smartphones, as well as Cisco wireless Internet protocol (IP) phones and other mobile devices. In January 2014, Vocera Communications Inc announced the acquisition of mVisum.

Communication solution can also be integrated with nurse call and other clinical systems to alert hospital workers to patient needs. The Company�� solutions are deployed in over 800 hospitals and healthcare facilities, including hospital systems, hospitals, and clinics, surgery centers and aged-care facilities. During the year ended December 31, 2011, the Company had shipped over 400,000 communication badges to its customers. The Company outsources the manufacturing of its products. Vocera offers a range of services, including clinical workflow design, wireless assessment, solution configuration, training and project management. It also provides a classroom-based curriculum for systems administrators, information technology professionals and clinical educators. The Company provides around-the-clock technical support to its customers through its support centers in San Jose, California, and Reading, United Kingdom.!

Voice Communication solution

The Company�� Voice Communication solution consists of a software platform that connects communication devices, including its hands-free, wearable, voice-controlled communication badges, Vocera-branded smartphones and third-party mobile devices that use its software applications to become part of the Vocera system. The system transforms the way mobile workers communicate by enabling them to connect with the right person simply by the name, function or group name of the person they want to reach, often while remaining at the point-of-care. Its system responds to over 100 voice commands.

Vocera�� Voice Communication solution is a software platform that runs on its customers��Windows-based servers. In addition, it controls the calling and messaging functions of the mobile client devices and maintains profiles for users and groups that enable customization of workflow patterns for each customer. The Company�� communication badge is a wearable device that operates over customers��wireless fidelity (Wi-Fi) networks. The badge is worn clipped to a shirt or on a lanyard. It can be used to conduct hands-free communication. It enables two-way voice conversations without the need to remember a phone number or use a handset. Its badge also incorporates automatic diagnostic mechanisms that feed data on wireless network performance back to the software platform for reporting and diagnosis of problems. In October 2011, it introduced the Vocera B3000 badge. In 2012, the Company added Cisco wireless IP phones to the list of mobile devices it supports.

Messaging solution

The Company�� Messaging solution delivers text messages, alerts and other information, directly to and from smartphones. Its solution consists of a software platform and client applications that run on BlackBerry, iPhone or Android devices. Its Messaging solution includes a range of client applications, including Alert, Chat and Commander.

Care! Transition Solution

The Company�� platform, which includes modules for patient transfers, shift changes, physician sign-outs and patient and family information exchanges, allows hospitals to standardize and monitor patient hand-offs. Its Care Transition solution can be deployed through either a hosted software-as-a-service model or as a server-on-site model and has been deployed by over 120 hospitals.

The Company competes with Cisco Systems, Ascom and Polycom.

Advisors' Opinion:
  • [By gurujx]

    Vocera Communications Inc (VCRA) Reached the 3-year Low of $12.33

    The prices of Vocera Communications Inc (VCRA) shares have declined to close to the 3-year low of $12.33, which is 64.4% off the 3-year high of $32.97.

  • [By Victor Selva]

    On Dec.24, Mario Gabelli, the Chairman and Chief Executive Officer of GAMCO Investors, Inc. added Communications Systems Inc. (JCS) at an average price of $11.05 and currently holds 330,172 shares of the stock. It was the 5th time he added the stock during this year, which makes me feel that he is betting in favor of a positive future for the consumption of network capacity.
    Recommendations of the Board
    Communications Systems is engaged in the manufacture and sale of modular connecting and wiring devices for voice and data communications, digital subscriber line filters, and structured wiring systems, and through its Transition Networks business unit in the manufacture of media and rate conversion products for telecommunications networks.
    Few months ago the firm announced�a series of actions to increase revenues and improve profitability. The first change was to operate as a holding company, monitoring and supporting all the business units: Suttle, Transition Networks (TN) unit and JDL Technologies. With this ��ew format�� each unit will operate with a high degree of autonomy. This will result in the reduction of labor costs, the emphasizing of accountability in the units as well as better recognition of performance. "While difficult decisions for the Board, we believe the changes we have taken to restructure our parent company as a holding company and to focus on individual business unit performance is in the best interest of our shareholders and will increase shareholder value" said Curtis A. Sampson, the Company's Board Chair and Interim CEO. Furthermore, strategic investments in the TN unit such as marketing, sales and product development will boost revenues in the future.
    Severe Warning Signs
    Not all are good news, we found three severe warning signs issued by GuruFocus: Piotroski F-Score of 2 is low, which usually implies poor business operation; revenue has been in decline over the past 3 years and operating margin has been in 5-year

  • [By Evan Niu, CFA]

    What: Shares of Vocera Communications (NYSE: VCRA  ) have gotten slaughtered by 38% today after the company reported earnings.

    So what: Revenue in the first quarter came in at $22.4 million, which translated into a non-GAAP net loss of $0.07 per share. Both figures were significantly worse than the $24.3 million in revenue and $0.02 per share adjusted loss that the Street was expecting. CEO Bob Zollars conceded that management was disappointed with the results.

Top 10 Medical Companies To Own For 2015: Sirona Dental Systems Inc (SIRO)

Sirona Dental Systems, Inc. (Sirona), incorporated on April 25, 1997, and its subsidiaries is a manufacturer of dental equipment, and is focused on developing, manufacturing and marketing solutions for dentists around the world. The Company operates in four segments: Dental CAD/CAM Systems, Imaging Systems, Treatment Centers and Instruments. The Company markets its products globally to dental practices, clinics and laboratories through an international network of distributors. The dental distributors supply both dental equipment and consumables, and have regular contact with the ultimate end-users. In addition, the Company also distributes its products through its own sales and services infrastructure.

Dental CAD / CAM Systems

Dental CAD/CAM Systems address the dental restorations, which includes several types of restorations, such as inlays, onlays, veneers, crowns, bridges, copings and bridge frameworks made from ceramic, metal or composite blocks. Sirona's CEramic REConstruction (CEREC) system is an in-office application that enables dentists to produce high quality restorations from ceramic material and insert them into the patient's mouth during a single appointment. The CEREC system consists of an imaging unit and a milling unit. The imaging unit scans the damaged area, captures the image of the tooth or teeth requiring restoration and proposes the specifications for the restoration. The milling unit then mills the ceramic restoration to the required specifications based upon the captured image and the dentist's design specifications.

Sirona offers a service contract on its CEREC product, which includes software updates and upgrades and maintenance on software-related hardware. In addition to CEREC, Sirona also offers CAD/CAM products for dental laboratories, including the inLab restoration fabrication system and the extra-oral inEos scanner. These products are designed to improve efficiency and reduce costs for the dental lab. The inLab system scans the ! models received from the dentists and then mills ceramic or composite block restorations, such as crown copings and bridge frameworks to the specifications of the captured image.

Imaging Systems

Imaging Systems comprise a broad range of systems for diagnostic imaging in the dental practice. Sirona has developed a comprehensive range of imaging systems for two dimensional (2D) or three dimensional (3D), panoramic and intra-oral applications. Intra-oral x-ray systems use image-capture sensor devices, which are inserted into the mouth behind the diagnostic area, and take images of one or two teeth. Panoramic x-ray systems produce images of the entire jaw structure by means of an x-ray tube and an image capture device, which rotates around the head.

Treatment Centers

Treatment Centers consists of a range of products from basic dentist chairs to chair-based units with integrated diagnostic, hygiene and ergonomic functionalities, as well as specialist centers used in preventative treatment and for training purposes. Sirona offers specifically configured products to meet the preferences of dentists within each region in which it operates. Sirona's treatment center configurations and system integration are designed to enhance productivity by creating a seamless workflow within the dental practice.

Instruments

Sirona offers a range of instruments, including handheld and power-operated handpieces for cavity preparation, endodontics, periodontology and prophylaxis, which are regularly updated and improved. The instruments are supplemented by multi-function tips, supply and suction hoses, as well as care and hygiene systems for instrument preparation. Sirona's instruments are often sold as packages in combination with treatment centers.

Advisors' Opinion:
  • [By Ben Levisohn]

    Shares of Align have surged 24% to $57 at 12:37 p.m. Sirona Dental Systems (SIRO) has risen 0.8% to $69.61, Dentsply International (XRAY) is up 0.1% at $45.44, Integra Lifesciences (IART) has� gained 0.4% to $44.23 and Danaher (DHR) has fallen 0.3% to $72.13.

  • [By John Udovich]

    Yesterday, small cap dental stock BIOLASE Inc (NASDAQ: BIOL) surged 17.69% after announcing it had received a license from the Health Canada-Medical Device Bureau to sell its EPIC dental soft-tissue diode laser systems throughout Canada, meaning its worth taking a closer look at the stock along with the performance of mid cap dental stocks like Sirona Dental Systems, Inc (NASDAQ: SIRO), DENTSPLY International Inc (NASDAQ: XRAY) and Align Technology, Inc (NASDAQ: ALGN).

  • [By Todd Campbell]

    Dentists may find that patients are more willing to spend on restorative procedures now that the job market is recovering and consumer sentiment is heading higher. That offers new opportunities for providers of dentistry equipment, such as Sirona Dental Systems (NASDAQ: SIRO  ) , a company that was spun out of Siemens in 1997 and brought public in 2006.

Top 10 Medical Companies To Own For 2015: Elan Corporation PLC (ELN)

Elan Corporation, plc (Elan), incorporated in December 1969, is a neuroscience-based biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. Elan�� business focuses on neurodegenerative diseases, such as Alzheimer�� disease and Parkinson�� disease; autoimmune diseases, including MS and Crohn�� disease and neo-epitope based targets for treatments across a range of therapeutic indications. Tysabri is a treatment for MS and Crohn�� disease that the Company markets and distributes with Biogen Idec. On September 16, 2011, Elan sold its EDT business to Alkermes, Inc. In November 2011, Elan launched a collaboration with the University of Cambridge, England, the Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre). On December 21, 2012, the Company completed the demerger of Prothena Corporation plc. In April 2013, it closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

Tysabri

Tysabri, which is an alpha-4 integrin inhibitor, is a therapy for MS, a neurological disorder involving central nervous system dysfunction among adults. Tysabri is approved in more than 65 countries. Tysabri is approved in the United States as a monotherapy for relapsing forms of MS, for patients who have had an inadequate response to, or are unable to tolerate, an alternative MS therapy. In the European Union, it is approved for relapsing-remitting MS (RRMS) in adult patients who have failed to respond to beta interferon or have rapidly evolving, severe RRMS. As of December 31, 2011, there were approximately 64,400 patients on Tysabri therapy worldwide.

In June 2011, the European Commission (EC) approved the inclusion of the anti-JCV antibody status as an additional factor in stratifying patients at risk for developing PML in the Summary of Product Characteristics��(SmPC) for Tysabri in the European Union. The Company has developed a two-step ! enzyme-linked immunosorbent assay (ELISA), STRATIFY JCV, with Biogen Idec. The assay detects anti-JCV antibodies in the blood of patients, and is commercially available in Europe. In January 2012, the FDA cleared the assay for commercial use in the United States. As of December 31, 2011, over 80,000 tests had been administered using the assay. Tysabri is marketed and distributed by Elan and Biogen Idec. The Company�� research group, Neotope, is focused on creating monoclonal antibodies based on neo-epitope targets for the treatment of a range of therapeutic indications.

Beta Amyloid Immunotherapies (AIP)

Beta amyloid immunotherapy includes the treatment of Alzheimer�� disease by inducing or enhancing the body�� immune response in order to clear toxic species of beta amyloid from the brain. The AIP includes bapineuzumab (intravenous and subcutaneous delivery) and ACC-001, as well as other compounds. Bapineuzumab is an experimental humanized monoclonal antibody delivered intravenously that is being studied as a treatment for mild to moderate Alzheimer�� disease. It is designed to provide antibodies to beta amyloid directly to the patient (passive immunotherapy).

ELND005, an A� Aggregation Inhibitor

The small molecule ELND005 (Scyllo-inositol) is a beta amyloid anti-aggregation agent. Preclinical data suggest that ELND005 may act through the mechanism of preventing and reversing the fibrilisation of beta amyloid (the aggregation of beta amyloid into clumps of insoluble oligomers). ELND005 may have additional applications in psychiatric indications, such as bipolar disorder. In November 2011, the Company entered into a manufacturing agreement for the supply of the active pharmaceutical ingredient for ELND005 with Lonza Group AG.

Neotope Biosciences Limited

Neotope Biosciences Limited (Neotope) is the Company�� wholly owned subsidiary that focuses on the discovery and development of antibodies to neo-epitope related targ! ets for t! he treatment of a range of indications. It includes amyloidosis, diabetes, cancer and macular degeneration. Neotope�� portfolio of targets includes alpha-synuclein for the potential treatment of synucleinopathies, such as Lewy body dementia and Parkinson�� disease, tau for Alzheimer�� disease and other tauopathies. It also has a program for type 2-diabetes.

Onclave Therapeutics Limited

Elan�� wholly owned subsidiary Onclave Therapeutics Limited (Onclave) was formed to develop assets originating from Elan that have application in oncology related diseases. Onclave�� program, NEOD001, which originated from Neotope, is being investigated for the treatment of AL amyloidosis, which is a fatal disease involving abnormal accumulation of amyloid in organs and tissue. During the year ended December 31, 2011, Onclave filed for orphan drug designation of NEOD001. Onclave�� pipeline includes additional compounds with relevance in diverse cancer indications.

The Company competes with Biogen Idec, Bayer Schering Pharma AG, Bayer Schering Pharma, Merck Serono, Pfizer, Teva Neurosciences, Inc., Sanofi-Aventis and Novartis AG.

Advisors' Opinion:
  • [By Tim Brugger]

    After confirming an unsolicited takeover bid from privately held investment firm Royalty Pharma in late February, Ireland-based Elan (NYSE: ELN  ) announced today that its board has unanimously rejected the offer.

  • [By Sarah Jones]

    Elan Corp. (ELN) fell 3.4 percent to 9.80 euros. Shareholders risk losing $2 billion by listening to the company�� board and rejecting Royalty Pharma�� takeover bid at a ballot next week.

  • [By Tim Brugger]

    After consulting with outside financial advisors, in conjunction with the Elan (NYSE: ELN  ) board of directors and executive management team, the Ireland-based biotechnology company has determined the recent $12.50-a-share buyout offer from Royalty Pharma undervalues select Elan assets by as much as $4.3 billion, the company announced Wednesday.

  • [By Brian Orelli]

    Most recently Elan (NYSE: ELN  ) spun out its drug discovery business into Prothena. Without the burden of a drug discovery unit, the parent company is now being pursued by Royalty Pharma, although Elan isn't keen on its current offer.

Wednesday, June 17, 2015

Positive Start to Q2 Earnings Season - Ahead of Wall Street

Top 5 Life Sciences Companies To Invest In Right Now

Tuesday, July 16, 2013

A largely tame inflation report, a positive looking Industrial Production reading, and strong earnings reports from Goldman Sachs (GS) and Johnson & Johnson (JNJ) provide the backdrop for today's trading action. Earnings and economic data aside, the market is looking forward to the Bernanke testimony to Congress tomorrow, likely his last one as the Fed Chairman. The Fed Chairman's comments last week were instrumental in easing QE related worries and he will likely be aiming for another do-no-harm type of performance tomorrow.

On the earnings front, the Goldman Sachs and JNJ reports were quite strong, while Coke (KO) came short of expectations on case-volume weakness. Including these three reports, we now have Q2 reports from 36 S&P 500 companies that combined account for 11.8% of the index's total market capitalization.

Total earnings for these 36 companies are up +19.2% from the same period last year, with 58.3% beating expectations. On the revenue side, we have a growth rate of +8.7% and 44.4% of the companies are coming ahead of top-line expectations. Of this morning's reports, Goldman and JNJ beat on the top- and bottom-lines, while Coke met EPS expectations, but missed on the top-line. The Q2 results thus far compare favorably with the 4-quarter average for the same set of 36 companies in terms of earnings and revenue growth rates, but a bit soft in terms of earnings and revenue beat ratios.

This is still fairly early going in the reporting cycle and these initial numbers will shift in the coming days. But the trend for the Finance sector will likely endure as we have Q2 reports now from more than a quarter of the sector's total market capitalization (26.1% to be precise). Total Finance sector earnings are up an impressive +33.3%, while the sector's revenues are up +1! 7.6%, a better performance than what we saw from the group in Q1 and the 4-quarter average. Bank of America (BAC) will report tomorrow.

The sector's earnings momentum is not surprising as it was all along expected to be the sole growth driver this quarter. There is not much growth outside of Finance, with the composite Q2 total earnings growth rate for the S&P 500 (combining the 36 reports that have come out with the 464 still to come) currently at +1.1%. Excluding the Finance sector's +24.1% growth rate, the composite Q2 earnings growth for the S&P 500 drops to a decline -3.4% from the same period last year.

We may not be seeing much earnings growth outside of Finance, but the overall 'level' of total earnings remains very high. Total earnings for the S&P 500 were at an all-time record level in Q1 and we will likely surpass that in Q2 as well. Consensus expectations are for a notable pick up in the growth pace in the second half of the year and beyond. Hard to envision those growth expectations panning out in a growth-constrained global economy, but that's what investors are pinning their hopes on.

The market has not paid much attention to negative estimate revisions in recent quarters, largely owing to the Fed's supportive role. But the Fed's plans to start pulling back on its QE program may force the market weigh the earnings picture a bit more closely. What they will find is an earnings picture that is not necessarily bad, but it's not worthy of pushing stocks to record levels either.

Sheraz Mian
Director of Research

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Tuesday, June 16, 2015

Best Value Companies To Invest In Right Now

Best Value Companies To Invest In Right Now: Dollar Tree Inc.(DLTR)

Dollar Tree, Inc. operates discount variety stores in the United States and Canada. Its stores offer merchandise primarily at the fixed price of $1.00. The company operates its stores under the names of Dollar Tree, Deal$, Dollar Tree Deal$, Dollar Giant, and Dollar Bills. Its stores offer consumable merchandise, including candy and food, and health and beauty care, as well as household consumables, such as paper, plastics, household chemicals, in select stores, and frozen and refrigerated food; variety merchandise, which includes toys, durable housewares, gifts, party goods, greeting cards, softlines, and other items; and seasonal goods, such as Easter, Halloween, and Christmas merchandise. As of April 30, 2011, it operated 4,089 stores in 48 states and the District of Columbia, as well as 88 stores in Canada. The company was founded in 1986 and is based in Chesapeake, Virginia.

Advisors' Opinion:
  • [By Rich Duprey]

    The dollar store operator at the center of a takeover bidding battle between two rival chains on Thursday reported fiscal 2015 first quarter earnings that were nearly cut in half as new pricing policies took effect. As Family Dollar (NYSE: FDO  ) continues struggling to turn around its operations, the subpar performance raises a legitimate question: Just what do Dollar Tree (NASDAQ: DLTR  ) and Dollar General (NYSE: DG  ) continue see in the chain that makes them think it's so valuable?

  • [By WWW.DAILYFINANCE.COM]

    Consumers and cooks have an expectation that mayonnaise should both taste and perform like mayonnaise.

    "Consumers and cooks have an expectation that mayonnaise should both taste and perform like mayonnaise. Just Mayo does neither," the complaint states, noting that the Hampton Creek product's oils separate when heate! d. Unilever holds the biggest share of the U.S. mayonnaise market, which is estimated to be worth $2 billion annually, according to market-research firm Euromonitor. That's more than twice the size of the ketchup market. Hampton Creek didn't return calls from The Associated Press seeking comment Tuesday morning. The company told The Wall Street Journal that it doesn't mislead consumers because it advertises the absence of eggs as a benefit. But a marketing professor hired by Unilever to survey consumers found in an online survey that more than half of thought Just Mayo was mayonnaise when they saw the label. The professor said in a document filed last week that 822 consumers participated in the research. Just Mayo is the first product from Hampton Creek, a San Francisco-based startup that touts the backing of Microsoft (MSFT) founder Bill Gates and Li Ka-shing, Asia's wealthiest person. Just Mayo is available at Dollar Tree (DLTR), Whole Foods Market (WFM) and Kroger (KR) stores, among other locations. Hellmann's celebrated its 100th anniversary last year. Mayonnaise originated in France in the 1700s, when a chef seeking to make a creamy sauce combined oil and egg yolks.

  • [By Ted Cooper]

    Family Dollar (NYSE: FDO  ) reported sales growth even as earnings per share fell amid a tough operating environment and ongoing merger preparations. The company expects to close on a takeover offer proposed by Dollar Tree (NASDAQ: DLTR  ) within the next few quarters. The merger-related restructuring charges and fees hurt the company's bottom line, but earnings fell even after adding back those expenses. Here's what it could mean for shareholders.

  • [By Rich Duprey]

    Suburban sprawl
    With more than 8,200 locations stretched across 46 states, Family Dollar is the second-largest dollar store chain, behind industry leader Dollar General (NYSE: DG  ) , which boasts more than 11,300 stores, and firmly ahead of No. 3 player Dollar Tree's ! (NASDAQ:! DLTR  )  5,100 stores.

  • source from Top Stocks For 2015:http://www.topstocksblog.com/best-value-companies-to-invest-in-right-now-3.html

Monday, June 15, 2015

Top 5 Clean Energy Stocks To Invest In 2016

Top 5 Clean Energy Stocks To Invest In 2016: Williams-Sonoma Inc.(WSM)

Williams-Sonoma, Inc. operates as a specialty retailer of home products. It offers culinary and serving equipment, including cookware, cookbooks, cutlery, informal dinnerware, glassware, table linens, specialty foods, and cooking ingredients; and bridal and gift items under the Williams-Sonoma brand name. The company also provides home furnishing categories, including furniture, textiles, decorative accessories, lighting, and tabletop items under the West Elm brand name; bed and bath products under the Pottery Barn brand name; and children?s furnishings and accessories under the Pottery Barn Kids brand name. Williams-Sonoma, Inc. sells its home products through four retail store concepts, which include Williams-Sonoma, Pottery Barn, Pottery Barn Kids, and West Elm; six direct-mail catalogs that comprise Williams-Sonoma, Pottery Barn, Pottery Barn Kids, Pottery Barn Bed and Bath, PBteen, and West Elm; and six e-commerce Websites, which consist of williams-sonoma.com, potte rybarn.com, potterybarnkids.com, pbteen.com, westelm.com, and wshome.com. As of January 30, 2011, it operated 592 stores, including 260 Williams-Sonoma, 193 Pottery Barn, 85 Pottery Barn Kids, 36 West Elm, and 18 outlet stores located in 44 states of the United States; Washington, D.C.; Canada; and Puerto Rico. The company was founded in 1956 and is headquartered in San Francisco, California.

Advisors' Opinion:
  • [By Peter Graham]

    The Q3 2014 earnings report for large cap home decor retailer Bed Bath & Beyond Inc (NASDAQ: BBBY), a potential peer of other furniture or home décor retailers like mid cap Williams-Sonoma, Inc (NYSE: WSM) and small caps Restoration Hardware Holdings Inc (NYSE: RH) and Pier 1 Imports Inc (NYSE: PIR), is scheduled for after the market closes on Thursday (January 8th). Aside from the Bed Bath &am! p; Beyond earnings report, it should be said that Williams-Sonoma, Inc reported Q3 2014 earnings on November 19th (they beat expectations when revenues grew 8.7% to $1.143 billion and EPS increased 17.2% to $0.68); Restoration Hardware Holdings Inc reported Q3 2014 earnings on December 10th (revenues increased 22% to $484.7 million and adjusted net income increased 56% to $20.3 million); and Pier 1 Imports Inc reported Q3 2015 earnings on December 18th (sales were up 4.1% to $484.5 million and net income was $17.9 million verses $26.8 million).

  • [By Omar Venerio]

    The first on the list is Williams-Sonoma Inc. (WSM), in which the fund disclosed a $326.3 million stake with 4.9 million shares. This stake represents 44.5% of the total portfolio. The company increased its e-commerce business. The key drivers of last year´s profitability were the new efficiencies reached in its worldwide supply chain, the increased traffic as well as the higher sales per square foot in retail stores.

  • [By Grace L. Williams]

    It wouldn’t be much of a shock. In an article earlier today, MarketWatch reporter Andria Cheng notes that industry rivals including Pier 1 Imports (PIR), the Container Store (TCS) and Williams-Sonoma (WSM) lowered their profit or sales outlooks. Cheng also notes that Bed Bach & Beyond had cut its outlook in June to $1.08 a share from $1.16. She continues:

  • [By Ben Levisohn]

    Shares of Williams-Sonoma (WSM) have tumbled today after the home-products retailer offered a disappointing outlook even as it met second-quarter earnings forecasts.

    Williams-Sonoma reported a profit of 53 cents a share, in line with estimates, on revenue of $1.04 billion, also meeting expectations. That alone would probably have been enough to send Williams-Sonoma’s shares lower since they were trading near a 52-week high right before the release. Throw in the sour guidance–Williams-Sonoma expected to earn $3.07 to $3.17 a share i! n 2014, b! elow forecasts for $3.21–and you have the recipe for destruction.

    Williams-Sonoma’s shares have dropped 11% to $66.75 at 10:20 a.m. Morgan Stanley’s Simeon Gutman and team explain why they downgraded Williams-Sonoma’s shares to Equal Weight despite the stock getting pounded today:

    While Q2 EPS was solid and in-line, we were expecting a carry-over in top-line momentum from previous quarters and comparable brand growth in the high single digits. We did not get this (Q2 comparable brand growth +5.7%), due to competition and tougher compares and now no longer believe the business will generate this level of growth in the near-term. Valuation (19x 2015e earnings) is not as supportive of a business that we now see generating low teens growth over the next 12 months.

    Williams-Sonoma’s PEG rate was elevated recently given positive earnings surprises. The PEG rate rose to ~1.6x vs. the one year average at 1.45x and the three year average of 1.3x. With earnings growth accelerating, this seemed appropriate and we believed these valuation levels would continue. But, with the rate of change moderating (albeit still healthy) the PEG may come back in. Even after tonight's stock move, there could be 2 turns of EPS multiple risk. The stock does not necessarily have much downside, but it could mark time as near-term earnings growth is digested.

    Gutman also lowere

  • source from Top Stocks For 2015:http://www.topstocksblog.com/top-5-clean-energy-stocks-to-invest-in-2016.html

Sunday, June 14, 2015

Top 10 Medical Companies To Watch For 2015

Fresenius Medical Care AG (FME) fell the most in more than four years in Frankfurt after the U.S. government proposed cutting payments to kidney dialysis center operators by 9.4 percent next year.

The shares dropped as much as 10 percent, the biggest intraday decline since October 2008. The stock was down 9.7 percent at 49.18 euros as of 9:11 a.m.

Much of the $1 billion reduction in payments is the result of a federal budget-balancing agreement. That deal targeted overspending on anemia drugs such as Amgen Inc. (AMGN)�� Epogen and Aranesp for patients in Medicare, the U.S. health plan for the elderly and disabled.

The U.S. government will consider phasing in the reduction over more than one year, the Health and Human Services Department said yesterday in a regulatory filing, citing concerns it may ��mpact beneficiary access to care.��The proposal is subject to public comment and may change before taking effect.

��his is a very dramatic cut,��Robert Sepucha, Bad Homburg, Germany-based Fresenius�� senior vice president for government affairs in the U.S., said by telephone. ��e��e concerned it would push dialysis clinics under the cost of care, which is not the right thing for Medicare to be doing.��

5 Best Railroad Stocks To Invest In 2016: Cell Therapeutics Inc (CTIC)

Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.

Pixuvri

As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.

OPAXIO

OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.

Tosedostat

In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.

Brostallicin

As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).

The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.

Advisors' Opinion:
  • [By John Udovich]

    The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns�plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many�� planned biotech IPOs that have recently been announced publicly:

  • [By MONEYMORNING]

    Cell Therapeutics Inc. (Nasdaq: CTIC), based in Seattle, Wash., acquires, develops, and commercializes treatments for cancers, including non-Hodgkin's leukemia and ovarian, neck, and brain cancers. The company just announced it has completed patient enrollment in clinical trials for an investigational agent to be used as a maintenance therapy in ovarian cancer patients. The trial is being conducted by the Gynecologic Oncology Group, one of the National Cancer Institute's funded research groups. Roth Capital recently reiterated a "Buy" rating on the stock and raised its price target from $6 to $7. Roth believes the company's treatment for leukemia, Pacritinib, is effectively evolving. Additionally, the investment firm sees potential in CTIC's Tosedostat, which deprives tumor cells of the amino acid building blocks needed to make proteins necessary for tumor cell survival. Shares rose 2% Tuesday to $3.52 on volume of 6 million shares.

  • [By Bryan Murphy]

    If you're reading this, then odds are you already know that the last two weeks (not even a full two weeks) have been more fruitful for Cell Therapeutics Inc. (NASDAQ:CTIC) shareholders than the prior two years have been - the stock's up 28% since last Thursday. And, odds are you already know why. The question most of you are asking now is, can CTIC actually keep climbing at this pace, or even keep climbing at any pace? The answer is "yes", though floating that answer almost inherently requires a deeper explanation.

  • [By Sean Williams]

    Cell Therapeutics (NASDAQ: CTIC  )
    Certainly no discussion of companies with large accumulated deficits would be complete without discussing a biotechnology company. It's perfectly understandable to see a biotech, especially a clinical-stage one, run with an accumulated deficit, as it takes time and money to build up a drug pipeline. However, after multiple complete response letters (the equivalent of a rejection) by the Food and Drug Administration and years without an approved drug, Cell Therapeutics racked up an astounding $1.83 billion in accumulated deficits through the end of fiscal 2012. By comparison, that's nearly 56 times larger than its shareholder equity.�

Top 10 Medical Companies To Watch For 2015: Cambridge Heart Inc (CAMH)

Cambridge Heart, Inc., incorporated on January 16, 1990, is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. The Company's products incorporate its technology for the measurement of Microvolt T-Wave Alternans (MTWA). The MTWA Test is conducted by elevating the patient's heart rate through exercise as performed on a treadmill similar to a stress test, pharmacologic agents, or pacing with electrical pulses.

The Company's products, including its first generation HearTwave System and second generation HearTwave II System, CH 2000 Cardiac Stress Test System, MTWA original equipment manufacturer (OEM) Module (MTWA Module) and Micro-V Alternans Sensors have received 510(k) clearance from the United States Food and Drug Administration (FDA) for sale in the United States. The Company's products have also received the Conformite Europeenne (CE) mark for sale in Europe. The Company's first generation HearTwave System, CH 2000 Cardiac Stress Test System and the HearTwave II System have been approved for sale by the Japanese Ministry of Health Labor and Welfare.

The Company's 510(k) clearance allows the Company's MTWA Test to be used to test patients with known, suspected, or at risk of ventricular tachyarrhythmia and/or sudden cardiac arrest, and allows the claim that its MTWA Test is predictive of those events. The MTWA Module is designed to work with existing cardiac stress test platforms distributed by other manufacturers as an add-on module to enable MTWA testing to be performed using the Company's Micro-V Alternans Sensors.

The Company's HearTwave II System, which has replaced the Company's original HearTwave System, is used to perform both MTWA testing and standard cardiac stress testing. In addition to MTWA measurement, the Company's HearTwave II System is a cardiac diagnostic system designed to support a range of customized protocols for the conduct of cardiac exercise stress testing. The Comp! any's Micro-V Alternans Sensors are single patient use, multi-segment electrodes. The Company's CH2000 is a cardiac diagnostic system designed to support a range of customized protocols for the conduct and measurement of cardiac exercise stress testing.

The Company competes with GE Medical Systems.

Advisors' Opinion:
  • [By Peter Graham]

    Last Friday, small cap stocks Cambridge Heart, Inc (OTCMKTS: CAMH), Abby Inc (OTCMKTS: ABBY) and Grillit Inc (OTCMKTS: GRLT) surged 176.92%, 71.2% and 24.07%, respectively. Of course, that was last week and today is a new trading week. So what should investors and traders alike be prepared for this week with these three small caps? Here is a closer look to help you decide on an investing or trading strategy:

    Cambridge Heart, Inc (OTCMKTS: CAMH) Recently Changed Its Board

    Small cap Cambridge Heart, Inc is a healthcare company engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. On Friday, Cambridge Heart, Inc surged 176.92% to $0.018 for a market cap of $1.80 million plus CAMH is up 20% since the start of the year and down 86.1% over the past five years according to Google Finance.

Top 10 Medical Companies To Watch For 2015: PTC Therapeutics Inc (PTCT)

PTC Therapeutics, Inc., incorporated on March 31, 1998 , is a biopharmaceutical company focused on the discovery and development of orally administered, small-molecule drugs that target post-transcriptional control processes. The Company�� lead product candidate includes ataluren, which is used for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation. Ataluren is in late stage clinical development for the treatment of Duchenne muscular dystrophy caused by nonsense mutations (nmDMD) and cystic fibrosis caused by nonsense mutations (nmCF).

Ataluren is orally administered small-molecule compound that targets nonsense mutations. The Company is engaged in the development of ataluren for the treatment of genetic disorders in, which a nonsense mutation is the cause of the disease. Genetic tests are available for many genetic disorders, including Duchenne muscular dystrophy and cystic fibrosis, to determine if the underlying cause is a nonsense mutation. The EMA has designated ataluren as an orphan medicinal product for the treatment of nmDMD and nmCF. During the year ended December 31, 2012, the Phase III clinical trial completed. The Company�� Ataluren clinical trials in patients with nonsense mutation genetic disorders include Ataluren for nmDMD: Phase 2b clinical trial complete; Confirmatory Phase III clinical trial initiated, and Ataluren for nmCF: Phase III trial completed.

Advisors' Opinion:
  • [By WWW.DAILYFINANCE.COM]

    Records fell on Wall Street Friday as another solid report on housing lifted the market for the second day in a row. There's a three-day weekend coming up -- something that often prompts investor caution -- but the gains were broad-based even though volume was fairly light. The VIX, which measures volatility, fell to its lowest level this year. The Dow Jones industrial average (^DJI) gained 63 points, the Nasdaq composite (^IXIC) rose 31, and the Standard & Poor's 500 index (^GPSC) added 8, topping the record high set last week. The Dow Transportation average also raced to an all-time high, lifted by airline stocks. United (UAL) soared more than 4 percent; Delta (DAL) gained more than 1 percent and Southwest (LUV) gained 2 percent. Southwest is at an all-time high, up 79 percent from a year ago. New home sales bounced back with a better than expected 6.4 percent increase last month. Lennar (LEN) and D.R. Horton (DHI) both rose 4 percent. Pulte (PHM), Beazer (BZH) and Hovnanian (HOV) also solid posted gains. Earnings continue to drive retail stocks. Gap (GPS) edged higher even though net fell. Foot Locker (FL) gained 1½ percent after topping expectations. GameStop (GME) rose 4 percent. Its net rose, helped by the rollout last year of new Xbox and PlayStation consoles. Zumiez (ZUMZ) rose 5½ percent on an earnings beat. But Aeropostale (ARO) tumbled 24 percent. Its loss widened and sales declined. The retailer continues to struggle with teen fashion trends. Also on the earnings front, TiVo (TIVO) rose 2 percent as it swung to a profit from a year ago loss. It also reported an increase in the number of subscribers. Hewlett-Packard (HPQ) rose 6 percent on news the company plans to eliminate up to 16,000 additional workers in an effort to cut costs. And several stocks extended big moves from yesterday. Best Buy (BBY) rose more than 3 percent for the second straight day after earnings beat expectations. Isis Pharmaceuticals (ISIS) jumped
  • [By John Kell]

    PTC Therapeutics Inc.(PTCT) said the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on the biopharmaceutical company’s marketing authorization application for its muscular dystrophy treatment. Shares slumped 21% to $20.60 in premarket trading.

Top 10 Medical Companies To Watch For 2015: Atossa Genetics Inc (ATOS)

Atossa Genetics Inc., incorporated on April 30, 2009, is a development-stage healthcare company focused on the prevention of breast cancer through the commercialization of diagnostic tests that can detect precursors to breast cancer, and through the research, development, and ultimate commercialization of treatments for pre-cancerous lesions. The Company�� diagnostic tests consist of medical devices cleared by the Food and Drug Administration (FDA), which can collect fluid samples from the breast milk ducts, where over 95% of breast cancers arise. During the fiscal year ended September 30, 2012, the tests that the Company offered and that are in development consist of ForeCYTE, ArgusCYTE, FullCYTE and NextCYTE. In September 2012, the Company acquired all of the assets of Acueity.

The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 73. The ArgusCYTE Breast Health Test provides information to help inform breast cancer treatment options and to help monitor potential recurrence. The FullCYTE Breast Health Test is designed to assess the individual breast ducts for pre-cancerous changes in women previously identified to be at high risk for breast cancer. The NextCYTE Breast Cancer Test is designed to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. MASCT, Oxy-MASCT, and its name and logo are the trademarks. ForeCYTE, FullCYTE, NextCYTE, and ArgusCYTE are its service marks.

Advisors' Opinion:
  • [By Bryan Murphy]

    You know, it's fun to be right about a particular stock, but at the same time, it's miserable if you didn't have the guts to actually act on the idea. That's my tale of woe with Atossa Genetics Inc. (NASDAQ:ATOS). On Monday of this week I was singing its praises, explaining how the chart suggested ATOS was on the verge of a breakout. But, I also suggested waiting for shares to take that one final confirming step.... a move above the 100-day moving average line. Now I wish I hadn't been so picky.

  • [By Roberto Pedone]

    One stock that's starting to push within range of triggering a big breakout trade is Apple (ATOS), which is involved in the prevention of breast cancer through the commercialization of diagnostic medical devices and laboratory developed tests that can detect precursors to breast cancer. This stock is off to a decent start in 2013, with shares up 24%.

    If you take a look at the chart for Atossa Genetics, you'll notice that this stock has been starting to uptrend over the last month, with shares moving higher from its low of $4.22 to its recent high of $5.08 a share. During that uptrend, shares of ATOS have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of ATOS within range of triggering a big breakout trade above a key downtrend line that dates back to May.

    Traders should now look for long-biased trades in ATOS if it manages to break out above some key overhead resistance levels at $5.08 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average volume of 74,575 shares. If that breakout hits soon, then ATOS will set up to re-test or possibly take out its next major overhead resistance levels at $5.60 to $6.23 a share. Any high-volume move above $6.23 will then put $7 to $7.50 into range for shares of ATOS.

    Traders can look to buy ATOS off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $4.42 or at $4.22 a share. One could also buy ATOS off strength once it takes out $5.08 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

  • [By Virginia Harrison]

    The other big Olympic sponsors are Visa (V, Fortune 500), Samsung (SSNLF), Panasonic (PCRFF), General Electric (GE, Fortune 500), Dow Chemical (DOW, Fortune 500), Procter & Gamble (PG, Fortune 500), Omega (OCFN) and Atos (ATOS). They're staying tight-lipped about the issue in public but a senior official at the International Olympic Committee said this month that several had raised concerns about how the law could affect the Games.

Top 10 Medical Companies To Watch For 2015: OncoMed Pharmaceuticals Inc (OMED)

OncoMed Pharmaceuticals, Inc. (OncoMed) incorporated on July 19, 2004, is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells (CSCs). It utilizes its technologies to identify, isolate and evaluate CSCs; identify and/or validate multiple potential targets and pathways critical to CSC self-renewal and differentiation; and develop targeted antibody and other protein-based therapeutics that are designed to modulate these CSC targets and inhibit the growth of CSCs. The Company's anti-cancer therapeutics include anti-DLL4 (demcizumab, OMP-21M18), Anti-DLL4/Anti-VEGF Bispecific, and Anti-Notch2/3 (OMP-59R5), Anti-Notch1 (OMP-52M51, Anti-Fzd7, Fzd8-Fc, RSPO-LGR.

Anti-DLL4 (demcizumab, OMP-21M18) is a humanized monoclonal antibody that inhibits Delta Like Ligand 4 (DLL4) in the Notch signaling pathway. The Company has completed a single-agent Phase Ia trial in advanced solid tumor patients. The Company focuses on conducting two Phase Ib combination trials of demcizumab. Anti-DLL4/anti-VEGF bispecific is a monoclonal antibody that targets and inhibits both DLL4 and vascular endothelial growth factor ( VEGF). VEGF is the target of Avastin. Anti-Notch2/3 (OMP-59R5) is a human monoclonal antibody that targets the Notch2 and Notch3 receptors.

Anti-Notch1 OMP-52M51 is a humanized monoclonal antibody targeted to the Notch1 receptor. Anti-Fzd7 OMP-18R5 is a human monoclonal antibody identified by screening against the Frizzled7 receptor (Fzd7) that binds a conserved epitope on five Frizzled receptors and inhibits Wnt signaling. OMP-18R5 is in a Phase I single-agent trial in advanced solid tumor patients. Fzd8-Fc OMP-54F28 is a fusion protein based on a truncated form of the Frizzled8 receptor ( Fzd8). RSPO-LGR ligands signal through the LGR receptor family.

The Company utilizes several robust technologies for the discovery and optimization of its antibody and protein-bas! ed therapeutics, including multiple proprietary technologies. Its antibody technologies include Mammalian Display Technology, Bispecific Antibody Technology, Hybridoma Technology. Mammalian Display Technology utilizes flow cytometry to isolate mammalian cells expressing antibodies on the cell surface with desired characteristics from large libraries of candidate antibodies. Bispecific Antibody Technology is used to generate its anti-DLL4/anti-VEGF antibody. Hybridoma Technology is used for isolating antibodies from mice, including multiplex single-cell screening techniques.

Advisors' Opinion:
  • [By WWW.DAILYFINANCE.COM]

    Stocks ended a mini-losing streak on Friday, led by upbeat news from Intel (INTC). The Dow Jones industrial average (^DJI) rose 41 points, after sliding more than 200 over the previous two days. The Nasdaq composite (^IXIC) gained 13 and the Standard & Poor's 500 index (^GPSC) added 6 points. Those modest gains did little to trim the loss for the week. The major averages posted their biggest weekly declines in more than two months. Intel is a component of all three big indexes, and it jumped 7 percent after raising its revenue guidance for the current quarter. The company sees stronger business demand for PCs than it previously expected. Intel shares are up 23 percent over the past six months. The Intel news had a ripple effect. Computer maker Hewlett-Packard (HPQ) rose more than 5 percent and Microsoft (MSFT) gained 1½ percent. Part of the increased demand Intel points to is tied to corporate buyers who need to replace their Windows XP machines, because Microsoft has stopped providing technical support for that platform. But Apple (AAPL) lost more than 1 percent. The stock is down since its 7-for-1 stock split took effect on Monday. There were two other big stories that had some legs beyond the companies directly involved. Open Table (OPEN) agreed to be acquired by Priceline (PCLN) for $2.6 billion. Open Table, which provides restaurant reservations, jumped 48 percent. Other online service providers rode the coattails of that deal. Yelp (YELP) gained 14 percent and Groupon (GRPN) gained 4 percent. In the retail arena, Express (EXPR) jumped 21 percent after a private equity firm took a 9.9 percent stake in the teen retailer and indicated it may make a buyout offer. That gave a boost to Aeropostale (ARO) and American Eagle (AEO), which both rose more than 2 percent. Abercrombie & Fitch (ANF) gained 1½. Elsewhere, International Game Technology (IGT) gained 10½ percent on a Reuters report that a bidding war could erupt for
  • [By Stephen Quickel]

    Recently, too, Celgene has formed a strategic partnership with OncoMed (OMED) to develop up to six anti-cancer stem-cell antibodies.

    Celgene itself has posted four successive quarters of revenue growth, which is expected to lift annual sales from $5.5 to $6.4 billion for calendar 2013, and to $7.5 billion in 2014. Despite its expanding size, earnings per share are projected to grow by 23.2% a year, by 28 Street analysts following its stock.

  • [By Jake L'Ecuyer]

    Equities Trading UP
    OncoMed Pharmaceuticals (NASDAQ: OMED) shot up 8.62 percent to $30.09 after the company initiated Phase 1B trial of WNT-parthway-target antibody. Jefferies lifted the price target on the stock from $27 to $46.

Top 10 Medical Companies To Watch For 2015: MiMedx Group Inc (MDXG)

MiMedx Group, Inc. (MiMedx), incorporated on February 28, 2008, is an integrated developer, manufacturer and marketer of regenerative biomaterial products processed from human amniotic membrane. The Company�� biomaterial platform technologies include the device technologies HydroFix and CollaFix, and tissue technologies, AmnioFix and EpiFix. Its tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through the Company�� donor program, mothers delivering full-term caesarian births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce a manipulated implant for homologous use. MiMedx is the supplier of amniotic tissue, having supplied over 100,000 implants to distributors and other equipment manufacturers (OEMs) for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

The Company has three platform technologies. Its largest addressable market is in chronic wound care consisting of diabetic, venous and pressure ulcers. On January 5, 2011, the Company acquired all of the outstanding equity interests in Surgical Biologics, LLC. Located in Kennesaw, Georgia, Surgical Biologics develops allografts and other products processed from human amniotic membrane that can be used for a range of medical applications, including ocular surface repair, gum repair, wound care, nerve and tendon repair, spine repair, burn treatment, and many other types of procedures that require the repair of a patient�� integumental (native) tissue. Surgical Biologics has developed a specialized process for the processing of amniotic membrane to produce a manipulated allograft for homologous use.

AmnioFix and EpiFix

MiMedx is the supplier of allografts processed from amniotic tissue, having supplied over 70,000 allografts to date for application in the Ophthalm! ic, Orthopedic, Dental, Spinal and Wound Care segments of healthcare. Its amnion products, AmnioFix and EpiFix, are processed from human tissue. The AmnioFix and EpiFix allografts can be used for a range of procedures, including ocular surface repair, gingival recession repair, wound care, burns, and many other types of procedures for the repair of a patient�� integumental (native) tissue. Its AmnioFix technology also is used as a graft to reduce the amount of scar tissue formation, provide a local anti-inflammatory and help with the soft tissue healing of the area. EpiFix offers a range of wound healing and wound care options. Much of the clinical usage of EpiFix has been for wound care patients suffering from diabetic ulcers, pressure ulcers, vein circulation ulcers, or artery circulation ulcers.

CollaFix

The Company�� CollaFix technology combines a means of creating fibers from soluble collagen and a specialized cross-linking process. MiMedx utilizes two separate cross-linking technologies for various applications. Initial laboratory and animal testing shows that the cross-linked collagen fibers produce a biocompatible, and durable construct that can be transformed into surgical meshes intended to treat a number of orthopedic soft-tissue trauma and disease disorders.

HydroFix

The Company licenses rights to a polyvinyl alcohol (PVA) polymer, which is a water-based biomaterial that can be manufactured with a range of mechanical properties, including those that appear to mimic closely the mechanical and physical properties of natural, healthy human tissue. This hydrogel has been used in other orthopedic and general surgery device applications, and it has demonstrated biocompatibility and durability inside the human body. It has a similar version of the product for the European market called HydroFix Spine Shield. The device is classified as a post-surgical adhesion inhibiting barrier and is used in specific spine surgeries. In December the original! HydroFix! Spine Shield (for Anterior use Class IIb in Europe) was renamed to be HydroFix Anterior Shield.

The Company competes with W.L. Gore & Associates, Inc. and Stryker.

Advisors' Opinion:
  • [By Garrett Cook]

    MiMedx Group (NASDAQ: MDXG) shares were also up, gaining 12.10 percent to $7.04 after the company reported Q2 earnings of $0.00 per share on revenue of $25.60 million and raised its FY14 sales outlook.

  • [By Rich Smith]

    MiMedx Group (NASDAQ: MDXG  ) ,�announced�Monday that results from a randomized controlled trial for its EpiFix wound-care allograft have been published in the International Wound Journal.�

    The clinical trial included patients with diabetic foot ulcers of at least four weeks' duration without infection, having adequate blood supply. Patients were broken into two groups, one receiving standard care alone, the other standard care plus EpiFix. After four and six weeks of treatment, the overall healing rate of patients treated with EpiFix was 77% and 92%, respectively, whereas standard care healed 0% and 8% of the wounds, respectively. The rate of healing with EpiFix exceeded that of standard treatment as well.

    According to the World Health Organization, diabetes will affect 366 million people worldwide -- up from 171 million in 2000.�Approximately 25% of diabetics will develop a chronic non-healing ulcer over their lifetime.�Diabetic foot ulcers�occur in 15% of all patients with diabetes and precede 84% of all lower leg amputations.

    EpiFix makes use of dehydrated human amniotic membrane to heal these ulcers. At room�temperature, EpiFix can have a shelf life of five years and retains the properties of the natural membrane.�Although there are similar, competing products on the market, the superior performance of�EpiFix compared with rival products (not yet proven by published studies) could help to make the company a market leader in the treatment of diabetic foot ulcers.

  • [By Bryan Murphy]

    It may not be as big as NuVasive, Inc. (NASDAQ:NUVA), and it might not be as sexy as MiMedx Group Inc. (NASDAQ:MDXG). But, Bacterin International Holdings Inc. (NYSEMKT:BONE) offers something to investors that MDXG and NUVA don't - can't - right now... a distinct opportunity for a lot of upside in a short amount of time.

Top 10 Medical Companies To Watch For 2015: Sirona Dental Systems Inc (SIRO)

Sirona Dental Systems, Inc. (Sirona), incorporated on April 25, 1997, and its subsidiaries is a manufacturer of dental equipment, and is focused on developing, manufacturing and marketing solutions for dentists around the world. The Company operates in four segments: Dental CAD/CAM Systems, Imaging Systems, Treatment Centers and Instruments. The Company markets its products globally to dental practices, clinics and laboratories through an international network of distributors. The dental distributors supply both dental equipment and consumables, and have regular contact with the ultimate end-users. In addition, the Company also distributes its products through its own sales and services infrastructure.

Dental CAD / CAM Systems

Dental CAD/CAM Systems address the dental restorations, which includes several types of restorations, such as inlays, onlays, veneers, crowns, bridges, copings and bridge frameworks made from ceramic, metal or composite blocks. Sirona's CEramic REConstruction (CEREC) system is an in-office application that enables dentists to produce high quality restorations from ceramic material and insert them into the patient's mouth during a single appointment. The CEREC system consists of an imaging unit and a milling unit. The imaging unit scans the damaged area, captures the image of the tooth or teeth requiring restoration and proposes the specifications for the restoration. The milling unit then mills the ceramic restoration to the required specifications based upon the captured image and the dentist's design specifications.

Sirona offers a service contract on its CEREC product, which includes software updates and upgrades and maintenance on software-related hardware. In addition to CEREC, Sirona also offers CAD/CAM products for dental laboratories, including the inLab restoration fabrication system and the extra-oral inEos scanner. These products are designed to improve efficiency and reduce costs for the dental lab. The inLab system scans the ! models received from the dentists and then mills ceramic or composite block restorations, such as crown copings and bridge frameworks to the specifications of the captured image.

Imaging Systems

Imaging Systems comprise a broad range of systems for diagnostic imaging in the dental practice. Sirona has developed a comprehensive range of imaging systems for two dimensional (2D) or three dimensional (3D), panoramic and intra-oral applications. Intra-oral x-ray systems use image-capture sensor devices, which are inserted into the mouth behind the diagnostic area, and take images of one or two teeth. Panoramic x-ray systems produce images of the entire jaw structure by means of an x-ray tube and an image capture device, which rotates around the head.

Treatment Centers

Treatment Centers consists of a range of products from basic dentist chairs to chair-based units with integrated diagnostic, hygiene and ergonomic functionalities, as well as specialist centers used in preventative treatment and for training purposes. Sirona offers specifically configured products to meet the preferences of dentists within each region in which it operates. Sirona's treatment center configurations and system integration are designed to enhance productivity by creating a seamless workflow within the dental practice.

Instruments

Sirona offers a range of instruments, including handheld and power-operated handpieces for cavity preparation, endodontics, periodontology and prophylaxis, which are regularly updated and improved. The instruments are supplemented by multi-function tips, supply and suction hoses, as well as care and hygiene systems for instrument preparation. Sirona's instruments are often sold as packages in combination with treatment centers.

Advisors' Opinion:
  • [By John Udovich]

    Yesterday, small cap dental stock BIOLASE Inc (NASDAQ: BIOL) surged 17.69% after announcing it had received a license from the Health Canada-Medical Device Bureau to sell its EPIC dental soft-tissue diode laser systems throughout Canada, meaning its worth taking a closer look at the stock along with the performance of mid cap dental stocks like Sirona Dental Systems, Inc (NASDAQ: SIRO), DENTSPLY International Inc (NASDAQ: XRAY) and Align Technology, Inc (NASDAQ: ALGN).